04/25/2011
Tags:
activated phenotype,
clinical research,
combinatorial strategies,
Contract Research Organizations (CROs),
CTLA-4,
cytotoxic T cells,
Dendritic cell function,
Drug treatments for melanoma,
helper T cells,
immune system,
ipilimumab,
melanoma specific T cells,
metastatic melanoma,
pre-clinical research,
rafting,
surface activation,
two-tiered strategyRecently, it was announced that the Food and Drug Administration has approved a breakthrough cancer medication from Bristol-Myers Squibb Co. that researchers have heralded as the first drug shown to prolong the lives of patients with advanced skin cancer. Share this:
03/11/2011
Tags:
Drug Development,
Immune Monitoring,
Immunogenicity,
Surrogate Markers of Efficacy,
Vaccine Development
It is of concern of all in pharma and biotech research fields that the number of vaccines and drugs that get to the market is very low compared to the number that enter phase I clinical trial testing. For this to change, among other improvements, new surrogate markers must be identified early on for the purpose of patient stratification, immune monitoring and/or therapeutic or prophylactic efficacy assessment.
03/10/2011
Tags:
Assay Standardization,
Cell Mediated Immune Assays,
Clinical Trials,
Correlates of Immunity,
Immune Monitoring
How practical is it to run validated and standardized cellular assays to interrogate biomarker surrogate correlates of immunity in clinical trial settings? Can this be done with any level of confidence in the outcome? Can these assays be performed routinely? Share this:
01/11/2011
Dr. Wade E. Bolton, president & CEO of ImmunoSite Technologies, moderated a special session on Cell Mediated Immunity (CMI) at the Phacilitate Vaccine Forum in Washington, DC, on Tuesday, January 25, 2011. Topics included: Do you want standardized assays to interrogate surrogate correlates of immunity? Do you need high-throughput, validated, and automated assays to measure immunogenicity? [...]
01/10/2011
IST quite literally helped “write the book” on cell analysis testing. They were asked to contribute a chapter of a book titled Validation of Cell-Based Assays in the GLP Setting: A Practical Guide, by authors/editors Uma Prabhakar and Marian Kelley (Publisher John Wiley and Sons, 2008, ISBN 0470028769, 9780470028766). Chapter 8 of this book entitled “Intracellular cytokine [...]
12/29/2010
ImmunoSite Technologies Has Been Working With The “CD4 Initiative” To Develop Quality Assurance Materials For Novel, Disposable, CD4 Point-Of-Care Test For Developing Nations The CD4 Initiative at Imperial College, London, funded by Bill and Melinda Gates Foundation grants, is nearing a major breakthrough in HIV/AIDS care by developing a simple, inexpensive CD4 point-of-care test specifically [...]
10/12/2010
“Difficulty is the excuse history never accepts.” Edward R. Murrow “In the middle of difficulty lies opportunity.” Albert Einstein “Quality is never an accident; it is always the result of high intention, sincere effort, intelligent direction and skillful execution; it represents the wise choice of many alternatives.” William A. Foster Designing a reproducible flow cytometry [...]
08/24/2010
Immune Monitoring and Surveillance: Essential To Innovations In the Fight Against Infectious Disease As an established leader in immune monitoring and surveillance, IST partners with leading organizations in research and development of infectious diseases. The researchers at ImmunoSite Technologies have been selected for numerous grant awards from early 2007 to late 2009 by a prestigious international group [...]
